Cary, N.C. – May 17, 2011 – Industry Standard Research (ISR) today announced the launch of a new and substantial research report titled “EDC and ePRO Market Overview and Outlook.” This report presents data and analysis from 107 interviews with Clinical Investigators and Site Coordinators from the US, Europe, and Asia. “‘Early adopter’ isn’t a term that most would use to describe drug development companies when it comes to incorporating new technologies into the drug development process”, explained Kevin Olson, CEO, ISR. “For the most part, there is good reason for this. It’s a highly regulated environment where the safety of clinical trial participants is paramount; not a recipe for frequent changes in process and infrastructure. That said, the growing reliance on electronic data capture (EDC) technologies over the past decade demonstrates drug companies will move to adopt new ways of doing business if the benefit is compelling and patient safety is not compromised. And we’re now beginning to see a similar move to adopt electronic patient reported outcomes (ePRO) technologies over paper diaries.” ISR’s new report profiles the current and future adoption of all major EDC and ePRO platforms. It also captures users’ experiences with these technologies and measures their satisfaction across a wide array of product attributes. Attributes tested include the Query Process, Page Load Speed, Integration Capabilities, and Technical Support, just to name a few. EDC vendors included in the assessment are: Datalabs, DATATRAK, DSG, eTrials, Medidata, Oracle, PhaseForward and Phoenix. ePRO vendors included are: Almac, Arrowhead, CRF Health, ERT, ICOPhone, invivodata, PHT, and Symfo. Olson went on to state: “On the surface, this information appears most valuable to the technology providers because it will allow them to capture a critical mass of user feedback at a point that’s critical in their products’ development lifecycles. However, sponsor and CRO companies themselves will benefit tremendously from the information. After all, it is their customers – in the form of investigators and study coordinators – who will either embrace or resent using a particular technology. And using one that is intuitive, feature-rich, and well supported can have a meaningful impact on trial timelines.” About Industry Standard Research Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our syndicated and custom research offerings, please visit the company’s Web site at or email